Follow The Filings

NMRA Neumora Therapeutics Inc.

Health Care, filed as NEUMORA THERAPEUTICS INC. (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 exit

In 2026 Q2 Nathan Fischel sold out of Neumora Therapeutics.

Who owns NMRA

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management exited 2026 Q2 Last 2026 Q1 0.03% Exit −0.03% 70,000 $137K History

0 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by NMRA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All NMRA insider trades
  • $15M bought by 3 insiders
  • $702K sold by 1 insider outside a trading plan
  • $307K sold by 1 insider under 10b5-1 plans
  1. Daljit Singh Aurora See Remarks
    Sale
    $270K 176,060 shares at $1.53
    Traded Aug 20–21 Filed Aug 21
    ↗
  2. Daljit Singh Aurora See Remarks
    Sale
    $432K 277,773 shares at $1.55
    Traded Aug 17–19 Filed Aug 19
    ↗
  3. Daljit Singh Aurora See Remarks
    Planned sale
    $307K 114,703 shares at $2.68 100% of stake
    Traded Nov 11, 2025 Filed Nov 13, 2025
    ↗
  4. Kristina Burow Director
    Buy
    $5M 1,915,700 shares at $2.61 +46% to stake
    Traded Oct 27, 2025 Filed Oct 29, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 16 option exercises and 4 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
8-K 2.02,5.02,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 1.01,2.03,2.05,7.01,8.01,9.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 3.02,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$235.92M -$243.79M -$236.93M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $478.28M $314.06M $190.54M
Total non-current assets * $17.92M $2.92M $0.51M
Total assets $496.2M $316.97M $191.05M
Total current liabilities $25.11M $29.89M $32.45M
Total non-current liabilities * $2.01M $0.022M $54.72M
Total equity $469.08M $287.06M $103.87M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$163.28M -$182.94M -$206.44M
Cash from investing $64.39M -$70.56M $168.52M
Cash from financing $231.94M $21.6M $77.09M
Net change in cash $133.04M -$231.89M $39.17M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.